This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Seelos Therapeutics, Inc. is a responsibly-driven company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.
Stock Performance
Seelos Therapeutics News 15 articles
- Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
- Seelos Therapeutics Announces Business Update on its Key Programs
- Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
- Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
- Seelos Therapeutics to Sponsor and Participate in Wonderland, the World’s Leading Psychedelic Event
- Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
- Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences
- Psychedelic Stock Market Update July 2022
- PRO: A Deeper Dive Into Seelos Therapeutics
- Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update
- Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note
- Seelos Therapeutics Doses First Patient in a Study of Intranasal Ketamine for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
- Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
- Seelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible Note
- Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)